Differentiation of Malignant and Benign Cardiac Tumors Using $^{18}$F-FDG PET/CT

Kambiz Rahbar¹, Harald Seifarth², Michael Schäfers³, Lars Stegger¹, Andreas Hoffmeier⁴, Tilmann Spieker⁵, Klaus Tiemann⁶, David Maintz², Hans Heinrich Scheld⁴, Otmar Schober¹, and Matthias Weckesser¹

¹Department of Nuclear Medicine, University of Münster, Münster, Germany; ²Department of Clinical Radiology, University of Münster, Münster, Germany; ³European Institute for Molecular Imaging, University of Münster, Münster, Germany; ⁴Department of Thoracic and Cardiovascular Surgery, University of Münster, Münster, Germany; ⁵Institute for Pathology, University of Münster, Münster, Germany; and ⁶Department of Cardiology, University of Münster, Münster, Germany

In the diagnostic algorithm of cardiac tumors, the noninvasive determination of malignancy and metastatic spread is of major interest to stratify patients and to select and monitor therapies. In the diagnostic work-up, morphologic imaging modalities such as echocardiography or magnetic resonance tomography offer information on, for example, size, invasiveness, and vascularization. However, preoperative assessment of malignancy may be unsatisfactory. The aim of this study was to evaluate the diagnostic value of $^{18}$F-FDG PET and the incremental diagnostic value of an optimized CT score in this clinical scenario. Methods: $^{18}$F-FDG PET/CT scans (whole-body imaging with low-dose CT) of 24 consecutive patients with newly diagnosed cardiac tumors were analyzed (11 men, 13 women; mean age ± SD, 59 ± 13 y). The maximum standardized uptake values (SUVmax) of the tumors were measured. Patients were divided into 2 groups: benign cardiac tumors (n = 7) and malignant cardiac tumors (n = 17) (cardiac primaries [n = 8] and metastases [n = 9]). SUVmax was compared between the 2 groups. Results were compared with contrast-enhanced CT, using standardized criteria of malignancy. Histology served as ground truth. Results: Mean SUVmax was 2.8 ± 0.6 in benign cardiac tumors and significantly higher both in malignant primary and in secondary cardiac tumors (8.0 ± 2.1 and 10.8 ± 4.9, P < 0.001). Malignancy was determined with a sensitivity of 100% and specificity of 86% (accuracy, 96%), after a cutoff with high sensitivity (SUVmax of 3.5) was chosen to avoid false-negatives. Morphologic imaging reached a sensitivity of 82% and a specificity of 86% (accuracy, 83%). Both false-positive and false-negative decisions in morphology could be corrected in all but 1 case using a metabolic threshold with an SUVmax of 3.5. In addition, extracardiac tumor manifestations were detected in 4 patients by whole-body $^{18}$F-FDG PET/CT. Conclusion: $^{18}$F-FDG PET/CT can aid the noninvasive preoperative determination of malignancy and may be helpful in detecting metastases of malignant cardiac tumors.

Primary cardiac tumors are rare, with an incidence ranging from 0.001% to 0.028% in autopsy reports. Approximately 20%–25% of these tumors are malignant, with angiosarcoma being the most common malignant cardiac tumor (1–3). In contrast, secondary cardiac tumors, such as metastasis to the heart from other malignant tumors, occur more frequently (4).

Because benign tumors can be resected completely in most cases, it is important to preoperatively differentiate between benign and malignant masses. This differentiation is essential, because most tumors are not suited for catheter-based biopsy. CT and MRI can depict several morphologic features that can be used to differentiate benign from malignant tumors and, in some cases, even provide a specific diagnosis (5–9). However, today, there is no routinely performed noninvasive imaging modality determining malignancy of cardiac tumors with sufficient accuracy. Molecular imaging methods such as $^{18}$F-FDG with PET can visualize tumor metabolism and thereby assess metabolic activity. PET, nowadays combined with CT into PET/CT, is a clinically established method to characterize tumors (10,11).

The use of $^{18}$F-FDG PET/CT to assess cardiac tumors is infrequently reported as single cases; the results of these reports are summarized in Table 1 (12–25). To date, larger patient groups undergoing whole-body $^{18}$F-FDG PET/CT to elucidate the diagnostic performance of PET/CT in cardiac tumors have not yet been published.

Therefore, the aim of this study was to evaluate the diagnostic value of $^{18}$F-FDG PET/CT with respect to preoperatively differentiating benign from malignant cardiac tumors.

Key Words: cardiac tumors; $^{18}$F-FDG PET/CT; cardiac angiosarcoma; cardiac metastases

DOI: 10.2967/jnumed.111.095364

Copyright 2012 by Society of Nuclear Medicine.
Primary and secondary malignant cardiac tumors show increased $^{18}$F-FDG uptake. In only 1 case of adenocarcinoma was $^{18}$F-FDG uptake absent.

+ = positive; NA = not available; – = negative.

**MATERIALS AND METHODS**

**Patients**

Twenty-four patients (11 men, 13 women; mean age ± SD, $59 ± 13$ y) with newly diagnosed cardiac tumors routinely undergoing $^{18}$F-FDG PET/CT (whole-body imaging with low-dose CT) as part of the initial assessment were retrospectively enrolled in this study. All patients were referred before treatment between 2004 and 2010 to screen for extracardiac tumor manifestations and to assess metabolism of the cardiac tumors.

Four of the 24 patients had a history of noncardiac tumors (time to cardiac tumor, 12.3 ± 8.1 y), which had been effectively treated in all cases.

On the basis of the histologic characterization of the surgically resected cardiac tumors ($n = 16$) or tumor biopsies ($n = 8$), patients were divided into 3 groups: benign primary cardiac tumors ($n = 7$), malignant primary cardiac tumors ($n = 8$), and secondary malignant cardiac tumors (metastases of other tumors or lymphoma involvement of the heart, $n = 9$). $^{18}$F-FDG uptake was compared among groups. For the purpose of calculating sensitivity and specificity, all malignant cardiac tumors were regarded as 1 group (Table 2).

The present study was performed according to local institutional guidelines and was approved by the ethics committee. Informed consent was obtained from all patients for the PET/CT procedure.

**Patient Preparation and PET/CT**

Details concerning the PET/CT procedures have been published elsewhere (26,27). To optimally suppress glucose uptake in the myocardium, which could conceal uptake of the cardiac tumors, all patients were studied after fasting for at least 6 h. Blood glucose levels at the time of $^{18}$F-FDG application were less than 120 mg/dL. A body-weight–adapted activity of $^{18}$F-FDG (5 MBq/kg of body weight) was injected intravenously (median, 68 min; range, 54–108 min) before PET data acquisition. All patients were asked to void their bladder immediately before scanning. The scans were obtained using a hybrid PET/CT system (Biograph Sensation 16; Siemens Medical Solutions). Low-dose CT of the entire area covered by PET (from skull base to the mid thigh level) was performed for attenuation correction in all patients. Simultaneous contrast-enhanced CT on the PET/CT scanner was acquired for 7 patients (29%). After completion of the CT scan, PET data were acquired for 3 min per bed position. PET images were reconstructed using the standard manufacturer-supplied software.

A separately acquired contrast-enhanced CT scan was available for 17 patients (71%). CT scans were obtained either on a 16-slice or on a 64-slice scanner (Somatom Sensation 16 or Somatom Definition; Siemens Medical Solutions), with a slice thickness of 1.0 or 0.75 mm. MRI was performed for 11 patients (46%; data not shown).

**Image Analysis**

Morphologic tumor characteristics were classified using CT by 2 board-certified radiologists. In addition to the size of the mass, the following 7 CT criteria of malignancy were systematically evaluated: contrast uptake, infiltration of the tumor into the surrounding tissue, infiltration of the tumor into the epicardium, irregular tumor margin, presence of necrosis, presence of pericardial effusion, and tumor involving more than 1 chamber. If 3 or more of these features were present, a mass was classified as malignant (Table 2).

$^{18}$F-FDG uptake in all cardiac tumors was quantified by calculating the maximum standardized uptake values ($SUV_{max}$) from 3-dimensional volumes of interest encompassing the tumor mass, equaling the decay-corrected regional radioactivity divided by the total injected dose and the body weight. In the case of low $^{18}$F-FDG uptake, CT images were used to identify the location and to set the volumes of interest. $SUV_{max}$ was correlated to the final diagnosis obtained by histology (Table 2).
To describe lesion-to-background contrast and to rule out artificial activity contribution by spillover of myocardial or blood 18F-FDG uptake into the tumor region, myocardial background tissue and blood-pool 18F-FDG uptake were also measured for all patients (Fig. 1). Circular regions of interest were placed over the myocardial tissue next to the tumor and in the lumen of the aorta ascendens (region of interest diameter, 10 mm). All PET/CT scans were reviewed and interpreted by 2 board-certified nuclear medicine physicians, who were aware of clinical signs and symptoms and of the tumor location but were unaware of the final diagnosis.

Statistics
Data were analyzed using standard statistical software (PASW Statistics 18; IBM). All data presented are mean value ± SD. A Kolmogorov–Smirnov test was performed to confirm normal distribution of the data. Patient groups were compared using the 2-sided Student \( t \) test for unpaired data. Significance was inferred at a level of \( P \) less than 0.05. Pearson correlation analysis was used to assess a relationship between tumor size and metabolic activity.

RESULTS

Glucose Uptake
For glucose uptake, the individual SUV\(_{\text{max}}\) is shown in Table 3, a graphical analysis is shown in Figure 1, and examples are shown in Figures 2–6. The 6-h fasting protocol kept 18F-FDG uptake low in the myocardium (mean standardized uptake value [SUV], 2.1 ± 0.6) and blood pool (mean SUV, 1.6 ± 0.4) in all patients, enabling delineation of hypermetabolic tumors from the myocardium (Fig. 3).

The mean 18F-FDG uptake (SUV) of the liver was 2.2 ± 0.6. In the 24 cardiac tumors, a 3- to 4-fold uptake was found (mean SUV\(_{\text{max}}, 7.5 \pm 3.7\) ). However, the range of uptake between tumor entities was large, from virtually no uptake to highly increased glucose uptake (SUV\(_{\text{max}}, 1.6–16.7\) ). Against background in the myocardium or blood, 16 of 24 tumors (66%) showed a positive contrast. There was

<table>
<thead>
<tr>
<th>Feature</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Positive predictive value</th>
<th>Negative predictive value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contrast enhancement</td>
<td>100%</td>
<td>0%</td>
<td>71%</td>
<td>NA</td>
</tr>
<tr>
<td>Infiltration of surrounding tissue</td>
<td>76%</td>
<td>86%</td>
<td>93%</td>
<td>60%</td>
</tr>
<tr>
<td>Involvement of epicardium</td>
<td>65%</td>
<td>86%</td>
<td>92%</td>
<td>50%</td>
</tr>
<tr>
<td>Irregular margin</td>
<td>82%</td>
<td>57%</td>
<td>82%</td>
<td>57%</td>
</tr>
<tr>
<td>Presence of necrosis</td>
<td>12%</td>
<td>100%</td>
<td>100%</td>
<td>32%</td>
</tr>
<tr>
<td>Pericardial effusion</td>
<td>41%</td>
<td>86%</td>
<td>88%</td>
<td>38%</td>
</tr>
<tr>
<td>Involvement of more than 1 chamber</td>
<td>71%</td>
<td>86%</td>
<td>86%</td>
<td>50%</td>
</tr>
<tr>
<td>3 or more features</td>
<td>82%</td>
<td>86%</td>
<td>93%</td>
<td>67%</td>
</tr>
<tr>
<td>Metabolic data</td>
<td>100%</td>
<td>86%</td>
<td>94%</td>
<td>100%</td>
</tr>
</tbody>
</table>

Sensitivity and specificity are shown for each criterion separately and for simultaneous presence of 3 or more features. NA = not available.

TABLE 2
Diagnostic Performance of Morphologic CT Features

FIGURE 1. Glucose uptake as quantified by 18F-FDG PET (SUV) in various cardiac tumors, myocardium, and blood. Uptake is consistently low in myocardium and blood. Malignant primary cardiac tumors show significantly higher glucose uptake than benign primary tumors. Malignant secondary cardiac tumors show mean glucose uptake comparable to that of malignant primary tumors; however, range is considerably larger.
# Table 3
Patient Characteristics

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age (y)</th>
<th>Sex</th>
<th>Location</th>
<th>Size (maximum diameter [mm])</th>
<th>Morphologic features</th>
<th>SUV&lt;sub&gt;max&lt;/sub&gt; Primary benign tumors</th>
<th>Primary malignant tumors</th>
<th>Secondary malignant tumors</th>
<th>Distant metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>71</td>
<td>M</td>
<td>RA, RV, intracavity</td>
<td>90</td>
<td>2</td>
<td>3.3 Fibroma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>48</td>
<td>M</td>
<td>LA, intracavity</td>
<td>36</td>
<td>1</td>
<td>1.6 Myxoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>73</td>
<td>F</td>
<td>LA, intracavity</td>
<td>25</td>
<td>2</td>
<td>2.7 Myxoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>77</td>
<td>M</td>
<td>LA, intracavity</td>
<td>30</td>
<td>2</td>
<td>4 Myxoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>83</td>
<td>F</td>
<td>RA, intracavity</td>
<td>18</td>
<td>2</td>
<td>2.6 Hematoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>59</td>
<td>F</td>
<td>LV, epicardial</td>
<td>35</td>
<td>3</td>
<td>2.4 Hemangioma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>83</td>
<td>F</td>
<td>LV, papillary muscle</td>
<td>20</td>
<td>2</td>
<td>3.1 Papillary fibroelastoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>61</td>
<td>F</td>
<td>LA, LV</td>
<td>50</td>
<td>6</td>
<td>5.3 Angiosarcoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>9</td>
<td>M</td>
<td>LV</td>
<td>86</td>
<td>4</td>
<td>5.4 Liposarcoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>48</td>
<td>F</td>
<td>RA, infiltrative</td>
<td>29</td>
<td>5</td>
<td>7.6 Angiosarcoma, Pulmonal, skeletal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>64</td>
<td>F</td>
<td>RA, RV, epicardial</td>
<td>124</td>
<td>5</td>
<td>9.8 Angiosarcoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>51</td>
<td>F</td>
<td>RV</td>
<td>50</td>
<td>3</td>
<td>10.7 Angiosarcoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>74</td>
<td>F</td>
<td>RA, cava superior and inferior</td>
<td>80</td>
<td>6</td>
<td>10.2 Angiosarcoma, Pulmonal, skeletal, liver</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>41</td>
<td>F</td>
<td>RA, epicardial fat</td>
<td>44</td>
<td>4</td>
<td>6.8 Angiosarcoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>71</td>
<td>M</td>
<td>RV</td>
<td>56</td>
<td>1</td>
<td>8.7 Liposarcoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>69</td>
<td>M</td>
<td>RA, cava inferior</td>
<td>65</td>
<td>1</td>
<td>3.8 Adenocarcinoma metastasis (pancreas)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>72</td>
<td>M</td>
<td>RA, cava inferior, intracavity</td>
<td>40</td>
<td>2</td>
<td>5.4 Hepatocellular carcinoma metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>59</td>
<td>M</td>
<td>RA, RV, cava superior</td>
<td>150</td>
<td>7</td>
<td>16.7 Lymphoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>71</td>
<td>F</td>
<td>RA, LV, cava superior</td>
<td>71</td>
<td>6</td>
<td>13.7 Lymphoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>44</td>
<td>M</td>
<td>RA, RV, LA, LV, pericardium</td>
<td>94</td>
<td>5</td>
<td>16.3 Malignant thymoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>52</td>
<td>M</td>
<td>LV, myocardium</td>
<td>60</td>
<td>6</td>
<td>8 Melanoma metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>35</td>
<td>F</td>
<td>LA, LV, myocardium</td>
<td>23</td>
<td>5</td>
<td>6.9 Rhabdomyosarcoma metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>54</td>
<td>M</td>
<td>RA, RV, intracavity</td>
<td>46</td>
<td>3</td>
<td>10.8 Synovial sarcoma metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>70</td>
<td>F</td>
<td>LV, LA, RV, pericardium</td>
<td>60</td>
<td>7</td>
<td>15.5 Vulva-carcinoma metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RA = right atrium; RV = right ventricle; LA = left atrium; LV = left ventricle; morphologic features = no. of features presented in Table 2.
a significant correlation between tumor size and SUV\textsubscript{max} ($R^2 = 0.42$). Tumor size as a diagnostic parameter for malignancy could not differ between benign and malignant tumors ($P = 0.33$).

In the 7 patients with benign primary cardiac tumors, glucose uptake was low, with a mean SUV\textsubscript{max} of 2.8 ± 0.6; these tumors typically did not exhibit a positive contrast to the myocardium and were visible on morphologic images only (Fig. 4).

In contrast, the 8 patients with malignant primary cardiac tumors (Fig. 5) showed an approximately 2.5 times higher mean SUV\textsubscript{max} than did those patients in the benign cardiac tumor group (Fig. 1; $P < 0.001$). Among the 8 patients with malignant primary cardiac tumors, there were 2 cases of skeletal metastases (25%); both patients had additional lung metastases and 1 had an additional liver metastasis. All cardiac primaries with metastases were angiosarcomas.

In the 9 cases with secondary cardiac tumors (Fig. 6) resulting from metastases, a mean SUV\textsubscript{max} of 10.8 ± 4.9 was found, with a relatively wide range of $^{18}$F-FDG uptake (range, 3.4–16.7). $^{18}$F-FDG uptake in secondary cardiac tumors was significantly higher than that in benign primary cardiac tumors ($P = 0.001$) and similar to that of malignant primary tumors ($P$ not statistically significant). In 2 of the 9 cases, previously unsuspected metastases were detected by $^{18}$F-FDG PET: skeletal metastases and an additional lung metastasis.

To evaluate the best cutoff value, a receiver-operating-characteristic analysis was performed. According to this analysis, 2 different cutoff values can be proposed: 3.5 and 4.6. An SUV\textsubscript{max} of 3.5 reveals a sensitivity of 100% and specificity of 86%, with a positive predictive value of 94% and a negative predictive value of 100%. With an SUV\textsubscript{max} of 4.6, the sensitivity drops to 94% and the specificity rises to 100%, with a positive predictive value of 100%.

CT

The diagnostic performance of the 7 morphologic characteristics and their combination is shown in Tables 2 and 3. All tumors showed contrast enhancement on CT. Fourteen of 17 malignant lesions were correctly classified with CT using the morphologic score (i.e., presence of 3 or more criteria; sensitivity, 82%) and only 1 benign lesion was misclassified as malignant (specificity, 85%). The 3 misclassified malignant lesions were 2 metastases (1 hepatocellular carcinoma and 1 adenocarcinoma arising from the pancreas) that protruded into the right atrium from the
inferior vena cava. The third misclassified lesion was a liposarcoma that involved only the right ventricle and showed only a broad attachment to the right ventricular wall but no clear sign of infiltration (Fig. 2). The misclassified benign lesion was a hemangioma situated in the epicardial fat next to the origin of the left coronary artery, which showed 3 features otherwise used to classify malignant tumors—namely, contrast enhancement, involvement of the epicardial fat, and pericardial effusion (Fig. 3). The receiver-operating-characteristic analysis revealed an optimal cutoff of 3 morphologic criteria, with a high specificity of 100% and a sensitivity of 70%. Using a threshold of malignancy of 4 or more morphologic criteria increased the positive predictive value to 100% at the cost of a lower sensitivity of 71%.

DISCUSSION

18F-FDG uptake reflects the metabolic rate of glycolysis in tumors and thus supplies additional information to morphologic imaging. Today, 18F-FDG PET has grown to be an important tool in the diagnostic management of patients with a variety of malignant tumors (10,11,28–31).

Overall, there is a correlation between the glucose accumulation in tumor tissue and the presence of malignancy, although exceptions are known (11,29,30,32,33). However, 18F-FDG PET has not yet been systematically evaluated for the characterization of cardiac tumors.

Contrast-enhanced CT visualizes several morphologic features that can help to differentiate benign from malignant tumors. In a series from Hoffmann et al., a location of the tumor outside the left heart, tissue inhomogeneity, and contrast enhancement were highly sensitive markers for malignancy, but the specificity of these features was rather low. On the other hand, the presence of a pericardial effusion was highly specific for malignant tumors (8). Similar to our study, tumor size was neither sensitive nor specific for ruling out malignancy. Other authors suggested that a well-defined tumor margin and the absence of tumor infiltration into adjacent structures are predictors for benign tumors (9), whereas infiltrative growth and lobulated margins were associated with malignancy (6). CT is currently recommended, especially for the evaluation of extracardiac masses that infiltrate into the pericardium or the heart itself (34) and to detect calcification (5); however, the extent of infiltration into the myocardium can best be appreciated in MRI. For both MRI and CT, several features have been described to differentiate benign from malignant lesions (34,35). However, because neither feature alone is efficient to differentiate benign from malignant lesions, we established a morphologic score that was helpful to differentiate benign from malignant lesions. Malignant tumors could be differentiated from benign lesions, with a sensitivity of 82% and a specificity of 86%, using this score. The score was created primarily for CT; therefore, signal intensities were not considered.

The present study shows that quantification of 18F-FDG uptake can support the noninvasive, pretreatment differentiation between benign and malignant cardiac tumors. The published cases of 18F-FDG PET uptake in cardiac tumors are in line with the results of the present study: malignant cardiac tumors typically exhibit a high 18F-FDG uptake. SUVmax was available in 7 cardiac malignancies only (mean ± SD, 8.8 ± 3.63; 9.5 ± 4.0 in the present study) (13–16,21,22,25). Benign cardiac tumors are expected to show only slight 18F-FDG uptake, although an exception was
reported of a myxoma presenting with high $^{18}$F-FDG uptake (12). Consistently, we found an SUV$_{\text{max}}$ of 2.8 ± 0.9, which was in the range of background myocardial and blood activity.

With a cutoff SUV$_{\text{max}}$ of 3.5, $^{18}$F-FDG PET could be used to noninvasively determine tumor malignancies with a sensitivity of 100% in our series. Only 1 benign tumor was misdiagnosed (specificity, 86%). Larger studies should further define the optimal cutoff.

Positive predictive value was 100% using a cutoff of 4 or more morphologic criteria. In these cases, PET is not necessary to evaluate for malignancy (12/24 in the present series). In patients with 3 or fewer morphologic criteria, PET was false-positive in 1 patient only. Twenty-three of 24 patients were correctly diagnosed (accuracy, 96%) and negative predictive value was 100% using the combined algorithm.

The main limitation of this study is its retrospective nature and the fact that no standard diagnostic pathway existed for patients presenting with cardiac tumors, resulting in heterogeneous data regarding the availability of CT and MRI. In the present series, most of the PET/CT scans were obtained for patients in whom other imaging modalities did not securely rule out malignancy. Because some benign lesions, especially myxomas, can be diagnosed with either echocardiography or MRI, these patients were not included in this retrospective analysis. Because the distribution of benign and malignant tumors does not reflect the incidence, a referral bias must be assumed.

Furthermore, uptake time, blood glucose levels, insulin medication, and equipment affect SUV measurements. Therefore, the SUV quantified in this case series may not reliably distinguish benign from malignant cardiac tumors in other institutions, using different scanning procedures. The diagnostic algorithm we suggest is valid only for this series and has to be evaluated in larger trials.

Finding a weak correlation between the size of tumors and the SUV$_{\text{max}}$ is at least partially due to the partial-volume effect. In the setting of cardiac tumors, the partial-volume effect originates from limited scanner resolution and from tumor movement introduced both by cardiac motion and by breathing.

The accuracy of fusion of the metabo-morphologic information may be greatly enhanced by correction of both PET and CT for respiratory and cardiac motion—not yet a standard procedure in clinical PET/CT (36,37).

For future studies, we propose a multicenter design including gated $^{18}$F-FDG PET/CT using the diagnostic criteria and cutoffs presented here. There may still be the need to optimize CT criteria, in particular to assess whether the number of criteria can be reduced to improve accuracy. The limited patient number excluded multivariate analysis of this issue.

CONCLUSION

In selected cases, $^{18}$F-FDG PET/CT provides incremental diagnostic information in the determination of malignancy and in staging. $^{18}$F-FDG PET/CT may gain importance in the therapeutic management of patients with cardiac tumors. Future prospective studies in larger patient groups are desirable to establish an optimal imaging pathway before therapy.

DISCLOSURE STATEMENT

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

ACKNOWLEDGMENTS

We thank the PET radiochemistry group at the Department of Nuclear Medicine for highly reliable production of $^{18}$F-FDG and the radiographers at the PET/CT for excellent technical assistance. This study was supported in part by the Sonderforschungsbereich SFB 656, Molecular Cardiovascular Imaging, Münster, Germany (projects C2 and C6), and the German Research Foundation (DFG) projects HO 4295/1-1 and SP 1249/2-1. No other potential conflict of interest relevant to this article was reported.

REFERENCES


Differentiation of Malignant and Benign Cardiac Tumors Using $^{18}$F-FDG PET/CT

Kambiz Rahbar, Harald Seifarth, Michael Schäfers, Lars Stegger, Andreas Hoffmeier, Tilmann Spieker, Klaus Tiemann, David Maintz, Hans Heinrich Scheld, Otmar Schober and Matthias Weckesser

*J Nucl Med.*
Published online: May 10, 2012.
Doi: 10.2967/jnumed.111.095364

This article and updated information are available at:
[http://jnm.snmjournals.org/content/early/2012/05/10/jnumed.111.095364](http://jnm.snmjournals.org/content/early/2012/05/10/jnumed.111.095364)

Information about reproducing figures, tables, or other portions of this article can be found online at:
[http://jnm.snmjournals.org/site/misc/permission.xhtml](http://jnm.snmjournals.org/site/misc/permission.xhtml)

Information about subscriptions to JNM can be found at:
[http://jnm.snmjournals.org/site/subscriptions/online.xhtml](http://jnm.snmjournals.org/site/subscriptions/online.xhtml)

*JNM* ahead of print articles have been peer reviewed and accepted for publication in *JNM*. They have not been copyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the *JNM* ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting, proofreading, and author review. This process may lead to differences between the accepted version of the manuscript and the final, published version.